<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:32:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4345866" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4345866</identifier>
        <datestamp>2015-03-10</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-id journal-id-type="publisher-id">jah3</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>Blackwell Publishing Ltd</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4345866</article-id>
              <article-id pub-id-type="pmcid">PMC4345866</article-id>
              <article-id pub-id-type="pmc-uid">4345866</article-id>
              <article-id pub-id-type="pmid">25713293</article-id>
              <article-id pub-id-type="pmid">25713293</article-id>
              <article-id pub-id-type="publisher-id">jah3856</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.114.001343</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group>
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Jiamin</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="au1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Masoudi</surname>
                    <given-names>Frederick A.</given-names>
                  </name>
                  <degrees>MD, MSPH</degrees>
                  <xref ref-type="aff" rid="au2"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spertus</surname>
                    <given-names>John A.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref ref-type="aff" rid="au3"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Qing</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="au1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Murugiah</surname>
                    <given-names>Karthik</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="au4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spatz</surname>
                    <given-names>Erica S.</given-names>
                  </name>
                  <degrees>MD, MHS</degrees>
                  <xref ref-type="aff" rid="au4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Jing</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="au1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Xi</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="au1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ross</surname>
                    <given-names>Joseph S.</given-names>
                  </name>
                  <degrees>MD, MHS</degrees>
                  <xref ref-type="aff" rid="au4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Krumholz</surname>
                    <given-names>Harlan M.</given-names>
                  </name>
                  <degrees>MD, SM</degrees>
                  <xref ref-type="aff" rid="au4"/>
                  <xref ref-type="author-notes" rid="jah3-856-note-0001">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jiang</surname>
                    <given-names>Lixin</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="au1"/>
                  <xref ref-type="author-notes" rid="jah3-856-note-0001">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>China PEACE Collaborative Group</collab>
                  <xref ref-type="author-notes" rid="jah3-856-note-0002">†</xref>
                </contrib>
                <aff id="au1">
                  <institution>National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, </institution>
                  <addr-line>Beijing, China (J.L., Q.W., J.L., X.L., L.J.)</addr-line>
                </aff>
                <aff id="au2">
                  <institution>Division of Cardiology, University of Colorado Anschutz Medical Campus, </institution>
                  <addr-line>Aurora, CO (F.A.M.)</addr-line>
                </aff>
                <aff id="au3">
                  <institution>Saint Luke's Mid America Heart Institute/University of Missouri‐Kansas City, </institution>
                  <addr-line>MO (J.A.S.)</addr-line>
                </aff>
                <aff id="au4">
                  <institution>Center for Outcomes Research and Evaluation, Yale‐New Haven Hospital, </institution>
                  <addr-line>New Haven, CT (K.M., E.S.S., J.S.R., H.M.K.)</addr-line>
                </aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><bold>Correspondence to:</bold> Lixin Jiang, MD, PhD, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, 167 Beilishi Rd, Beijing 100037, China. E‐mail: <email>jiangl@fwoxford.org</email></corresp>
                <fn fn-type="con" id="jah3-856-note-0001">
                  <label>*</label>
                  <p>Dr Krumholz and Dr Jiang are joint senior authors.</p>
                </fn>
                <fn id="jah3-856-note-0002">
                  <label>†</label>
                  <p>The China PEACE‐Retrospective AMI Study Site Investigators are listed in an Appendix available at <ext-link ext-link-type="uri" xlink:href="http://jaha.ahajournals.org/content/1/5/e001343/suppl/DC1">http://jaha.ahajournals.org/content/4/2/e001343/suppl/DC1</ext-link></p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <month>2</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>2</month>
                <year>2015</year>
              </pub-date>
              <volume>4</volume>
              <issue>2</issue>
              <elocation-id>e001343</elocation-id>
              <history>
                <date date-type="received">
                  <day>06</day>
                  <month>8</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>09</day>
                  <month>1</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
</copyright-statement>
                <copyright-year>2015</copyright-year>
                <license license-type="creative-commons">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution‐NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Chinese and U.S. guidelines recommend angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for all patients with acute myocardial infarction (AMI) in the absence of contraindications as either a Class I or Class IIa recommendation. Little is known about the use and trends of ACEI/ARB therapy in China over the past decade.</p>
                </sec>
                <sec>
                  <title>Methods and Results</title>
                  <p>Using nationally representative data from the China Patient‐centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE‐Retrospective AMI Study), we assessed use of ACEI/ARB therapy in 2001, 2006, and 2011, overall and across geographic regions and strata of estimated mortality risk, and predictors of ACEI/ARB therapy, among patients with Class I indication by Chinese guidelines. The weighted rate of ACEI/ARB therapy increased from 62.0% in 2001 to 71.4% in 2006, decreasing to 67.6% in 2011. Use was low across all 5 geographic regions. By strata of estimated mortality risk, in 2001, rates of therapy increased with increasing risk; however, by 2011, this reversed and those at higher risk were less likely to be treated (70.7% in lowest‐risk quintile vs. 63.5% in the highest‐risk quintile; <italic>P</italic>&lt;0.001).</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>One third of Chinese AMI patients with Class I indications do not receive ACEI/ARB therapy during hospitalization, with little improvement in rates over time. Patients at higher mortality risk in 2011 were less likely to be treated, highlighting important opportunities to optimize the use of this cost‐effective therapy.</p>
                </sec>
                <sec>
                  <title>Clinical Trial Registration</title>
                  <p>URL: ClinicalTrials.gov. Unique identifier: NCT01624883.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>acute myocardial infarction</kwd>
                <kwd>angiotensin‐converting enzyme inhibitors</kwd>
                <kwd>quality of care</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="other">
              <title>Introduction</title>
              <p>Angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been shown to reduce the risk of mortality and major adverse cardiovascular (CV) events in patients with acute myocardial infarction (AMI) in randomized, clinical trials.<sup><xref rid="b1" ref-type="bibr">1</xref>–<xref rid="b4" ref-type="bibr">4</xref></sup> Chinese and U.S. guidelines endorse the use of these agents early after AMI.<sup><xref rid="b5" ref-type="bibr">5</xref>–<xref rid="b11" ref-type="bibr">11</xref></sup> The benefit of therapy is likely greatest in the highest‐risk patients, for whom the consequences of undertreatment can be particularly significant.<sup><xref rid="b5" ref-type="bibr">5</xref>–<xref rid="b11" ref-type="bibr">11</xref></sup></p>
              <p>As a cost‐effective, widely available therapy,<sup><xref rid="b12" ref-type="bibr">12</xref></sup> ACEI/ARB is particularly important in China, which faces challenges in caring for an increasing number of patients with AMI in the setting of limited resources. It is estimated that, by 2030, up to 23 million people will suffer an AMI in China.<sup><xref rid="b13" ref-type="bibr">13</xref></sup> Recognizing that acute CV care for patients with AMI in China is provided in diverse settings, and frequently in hospitals without advanced CV services,<sup><xref rid="b14" ref-type="bibr">14</xref></sup> it is critical to ensure the universal application of therapies such as ACEI/ARB. Understanding contemporary trends in the use of ACEI/ARB in China can guide quality improvement efforts both domestically and may stimulate such studies in other low‐ and middle‐income countries facing a similar growing burden of CV disease (CVD).</p>
              <p>Accordingly, we analyzed a large, nationally representative sample of AMI patients admitted to Chinese hospitals in 2001, 2006, and 2011, from the China Patient‐centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE‐Retrospective AMI Study). We sought to determine: (1) rates of ACEI/ARB use among eligible patients during AMI hospitalization and trends in use over time; (2) rates and trends of use across geographic regions; (3) patient and hospital characteristics associated with ACEI/ARB therapy; and (4) rates of use stratified by estimated mortality risk, given that ideal care would preferentially target higher‐risk individuals. This government‐sponsored study sought to inform practice and policy, as well as serve as a prelude for quality improvement initiatives to optimize treatment of patients with AMI in China.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Design Overview of China PEACE‐Retrospective AMI Study</title>
                <p>The design of the China PEACE‐Retrospective AMI Study has been published previously.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> In brief, we created a nationally representative sample of hospitalizations for AMI during 2001, 2006, and 2011 with a 2‐stage random sampling design. In the first stage, we identified hospitals using a simple random sampling procedure within each of the 5 study strata: Eastern‐rural, Central‐rural, Western‐rural, Eastern‐urban, and Central/Western‐urban regions, given that hospital volumes and clinical capacities differ between urban and rural areas as well among the 3 official economic‐geographic regions (Eastern, Central, and Western) of Mainland China. We grouped Central and Western urban regions together given their similar per capita income and health services capacity. In the 3 rural strata, the sampling framework consisted of the central hospital in each of the predefined rural regions (2010 central hospitals in 2010 rural regions). In the 2 urban strata, the sampling framework consisted of the highest‐level hospitals in each of the predefined urban regions (833 hospitals in 287 urban regions; <xref ref-type="fig" rid="fig01">Figure 1</xref>). Because the majority of hospitals in China are publicly owned and administered, hospital closure is rare. We selected representative hospitals from 2011 to reflect current practice and trace this cohort backward to 2006 and 2001 to describe temporal trends. In the second stage, we drew cases based on the local hospital database for patients with AMI in each year at each sampled hospital using systematic random sampling procedures. Patients with AMI were identified using International Classification of Diseases, Clinical Modification, codes, including versions 9 (410.xx) and 10 (I21.xx), when available or through principal discharge diagnosis terms.</p>
                <fig id="fig01" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Study sample profile. ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g1"/>
                </fig>
                <p>We sampled 175 hospitals, of which 7 did not have any admissions for AMI and 6 declined participation. Examination of patient databases from participating 162 hospitals yielded 31 601 hospitalizations for AMI in 2001, 2006, and 2011. We sampled 18 631 cases and finally acquired medical records for 18 110 (97.2%). After excluding those with noninterpretable medical charts, duplicates, not confirmed AMI, cases outside the study periods, and in‐hospital AMI events, we identified 16 100 cases with available medical charts (<xref ref-type="fig" rid="fig01">Figure 1</xref>).</p>
                <p>The central ethics committee at the China National Center for Cardiovascular Diseases approved the China PEACE‐Retrospective AMI Study. All collaborating hospitals accepted the central ethics approval except for 5 hospitals, which obtained local approval by internal ethics committees.</p>
              </sec>
              <sec>
                <title>Study Sample</title>
                <p>Patients with AMI eligible for ACEI/ARB therapy were identified as follows: Only those patients with a definite discharge diagnosis of AMI were included in the study sample. We excluded patients with a hospital length of stay shorter than 24 hours because they might not have had adequate opportunity to receive ACEI/ARB. We also excluded patients who were transferred in from another hospital, given that information regarding ACEI/ARB therapy at their presenting hospital was unknown. In addition, we excluded patients with the following contraindications to ACEI/ARB: history of allergy to ACEI/ARB; hyperkalemia (serum potassium [K<sup>+</sup>] &gt;5.5 mmol/L); creatinine (Cr) &gt;3 mg/dL (265 μmol/L); or pregnancy/breast feeding.<sup><xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b16" ref-type="bibr">16</xref></sup> To capture the lab values influencing the decision‐making process, we used the last lab value of K<sup>+</sup> and Cr before administration of the medication for patients who received ACEI/ARB, and for those who did not receive ACEI/ARB therapy, we used the highest lab value during the hospitalization. Because the Cr level influencing the decision to use ACE/ARB may vary among providers, we performed a sensitivity analysis excluding patients with Cr ≥1.5 mg/dL (133 μmol/L) during hospitalization.</p>
                <p>To assess appropriate usage of ACEI/ARB therapy during hospitalization, we separated eligible patients according to Chinese guidelines into 2 groups: (1) Class I recommendation group (Chinese Class I), which included all patients with ST‐elevation myocardial infarction (STEMI), and those patients with non‐ST‐elevation myocardial infarction (NSTEMI) and either heart failure (HF), left ventricular (LV) dysfunction (LV ejection fraction [LVEF] &lt;40%), hypertension (HTN), or diabetes mellitus; (2) Class IIa recommendation group (Chinese Class IIa), which included patients with NSTEMI who do not have a Class I indication for receiving ACEI/ARB.<sup><xref rid="b9" ref-type="bibr">9</xref>–<xref rid="b11" ref-type="bibr">11</xref></sup> The diagnosis of AMI type (STEMI vs. NSTEMI) was determined by the combination of clinical discharge diagnosis terms and electrocardiogram (ECG) results. If the local diagnosis was not definitive, cardiologists at the coordinating center reviewed the medical record and ECG to establish diagnosis. We treated left bundle branch block as a STEMI equivalent.<sup><xref rid="b17" ref-type="bibr">17</xref></sup></p>
                <p>Moreover, because doctors in China frequently refer to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, we also performed a secondary analysis by grouping patients according to ACC/AHA guidelines. The ACC/AHA Class I recommendation group included STEMI patients with LVEF ≤40%, HTN, diabetes, chronic kidney disease, HF, or anterior MI; and NSTEMI patients with LVEF ≤40%, HTN, diabetes, or HF. The ACC/AHA Class IIa recommendation group included STEMI and NSTEMI patients who do not meet a Class I recommendation for ACEI/ARB.<sup><xref rid="b5" ref-type="bibr">5</xref>–<xref rid="b8" ref-type="bibr">8</xref></sup></p>
              </sec>
              <sec>
                <title>Data Collection</title>
                <p>Data were collected by centralized medical record abstraction using standardized data definitions. The following variables were collected: demographics, admission year, medical history, CV risk (CVR) factors, and clinical characteristics on admission and during hospitalization. Hospital characteristics were collected by a hospital survey. Details of these variables are shown in <xref ref-type="table" rid="tbl01">Table 1</xref>. We adopted rigorous monitoring at each stage to ensure data quality.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> Data quality was monitored by randomly auditing 5% of the medical records, which demonstrated an overall variable agreement of &gt;98%.</p>
                <table-wrap id="tbl01" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Patient and Hospital Characteristics Among Patients With a Chinese Class I Indication for ACEI/ARB, Overall and Stratified by Receipt of ACEI/ARB Therapy During Hospitalization</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Characteristics</th>
                        <th align="center" rowspan="1" colspan="1">Total (%) (N=13 486)</th>
                        <th align="center" rowspan="1" colspan="1">Received ACEI/ARB (%) (N=9008)</th>
                        <th align="center" rowspan="1" colspan="1">Did not Receive ACEI/ARB (%) (N=4478)</th>
                        <th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Demographic</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">0.16</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;55</td>
                        <td align="char" rowspan="1" colspan="1">22.2</td>
                        <td align="char" rowspan="1" colspan="1">21.6</td>
                        <td align="char" rowspan="1" colspan="1">23.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">55 to 64</td>
                        <td align="char" rowspan="1" colspan="1">23.7</td>
                        <td align="char" rowspan="1" colspan="1">23.8</td>
                        <td align="char" rowspan="1" colspan="1">23.3</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">65 to 74</td>
                        <td align="char" rowspan="1" colspan="1">30.1</td>
                        <td align="char" rowspan="1" colspan="1">30.4</td>
                        <td align="char" rowspan="1" colspan="1">29.6</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥75</td>
                        <td align="char" rowspan="1" colspan="1">24.0</td>
                        <td align="char" rowspan="1" colspan="1">24.1</td>
                        <td align="char" rowspan="1" colspan="1">23.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gender</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">0.30</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Male</td>
                        <td align="char" rowspan="1" colspan="1">69.9</td>
                        <td align="char" rowspan="1" colspan="1">70.2</td>
                        <td align="char" rowspan="1" colspan="1">69.3</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female</td>
                        <td align="char" rowspan="1" colspan="1">30.1</td>
                        <td align="char" rowspan="1" colspan="1">29.8</td>
                        <td align="char" rowspan="1" colspan="1">30.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Cardiovascular risk factors</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="char" rowspan="1" colspan="1">52.4</td>
                        <td align="char" rowspan="1" colspan="1">60.4</td>
                        <td align="char" rowspan="1" colspan="1">36.4</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes</td>
                        <td align="char" rowspan="1" colspan="1">20.6</td>
                        <td align="char" rowspan="1" colspan="1">22.5</td>
                        <td align="char" rowspan="1" colspan="1">16.9</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Current smoker</td>
                        <td align="char" rowspan="1" colspan="1">34.9</td>
                        <td align="char" rowspan="1" colspan="1">35.3</td>
                        <td align="char" rowspan="1" colspan="1">34.1</td>
                        <td align="char" rowspan="1" colspan="1">0.15</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Medical history</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="char" rowspan="1" colspan="1">11.5</td>
                        <td align="char" rowspan="1" colspan="1">11.9</td>
                        <td align="char" rowspan="1" colspan="1">10.8</td>
                        <td align="char" rowspan="1" colspan="1">0.07</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Chronic renal insufficiency</td>
                        <td align="char" rowspan="1" colspan="1">1.9</td>
                        <td align="char" rowspan="1" colspan="1">1.9</td>
                        <td align="char" rowspan="1" colspan="1">1.8</td>
                        <td align="char" rowspan="1" colspan="1">0.68</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Coronary heart disease</td>
                        <td align="char" rowspan="1" colspan="1">22.6</td>
                        <td align="char" rowspan="1" colspan="1">23.5</td>
                        <td align="char" rowspan="1" colspan="1">20.6</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="char" rowspan="1" colspan="1">10.8</td>
                        <td align="char" rowspan="1" colspan="1">11.4</td>
                        <td align="char" rowspan="1" colspan="1">9.7</td>
                        <td align="char" rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Clinical characteristics during hospitalization</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">AMI type</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anterior STEMI</td>
                        <td align="char" rowspan="1" colspan="1">42.4</td>
                        <td align="char" rowspan="1" colspan="1">44.6</td>
                        <td align="char" rowspan="1" colspan="1">37.9</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non‐anterior STEMI</td>
                        <td align="char" rowspan="1" colspan="1">45.8</td>
                        <td align="char" rowspan="1" colspan="1">42.4</td>
                        <td align="char" rowspan="1" colspan="1">52.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NSTEMI</td>
                        <td align="char" rowspan="1" colspan="1">11.8</td>
                        <td align="char" rowspan="1" colspan="1">13.0</td>
                        <td align="char" rowspan="1" colspan="1">9.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cardiac arrest</td>
                        <td align="char" rowspan="1" colspan="1">2.8</td>
                        <td align="char" rowspan="1" colspan="1">2.6</td>
                        <td align="char" rowspan="1" colspan="1">3.1</td>
                        <td align="char" rowspan="1" colspan="1">0.09</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cardiogenic shock</td>
                        <td align="char" rowspan="1" colspan="1">6.2</td>
                        <td align="char" rowspan="1" colspan="1">5.0</td>
                        <td align="char" rowspan="1" colspan="1">8.6</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart failure</td>
                        <td align="char" rowspan="1" colspan="1">34.6</td>
                        <td align="char" rowspan="1" colspan="1">37.3</td>
                        <td align="char" rowspan="1" colspan="1">29.0</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Atrial fibrillation</td>
                        <td align="char" rowspan="1" colspan="1">9.4</td>
                        <td align="char" rowspan="1" colspan="1">9.5</td>
                        <td align="char" rowspan="1" colspan="1">9.3</td>
                        <td align="char" rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP, mm Hg</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;90</td>
                        <td align="char" rowspan="1" colspan="1">4.1</td>
                        <td align="char" rowspan="1" colspan="1">2.4</td>
                        <td align="char" rowspan="1" colspan="1">7.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">90 to 139</td>
                        <td align="char" rowspan="1" colspan="1">58.5</td>
                        <td align="char" rowspan="1" colspan="1">53.8</td>
                        <td align="char" rowspan="1" colspan="1">68.2</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥140</td>
                        <td align="char" rowspan="1" colspan="1">37.4</td>
                        <td align="char" rowspan="1" colspan="1">43.8</td>
                        <td align="char" rowspan="1" colspan="1">24.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart rate, beats/min</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;60</td>
                        <td align="char" rowspan="1" colspan="1">12.3</td>
                        <td align="char" rowspan="1" colspan="1">10.8</td>
                        <td align="char" rowspan="1" colspan="1">15.3</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">60 to 90</td>
                        <td align="char" rowspan="1" colspan="1">65.8</td>
                        <td align="char" rowspan="1" colspan="1">66.3</td>
                        <td align="char" rowspan="1" colspan="1">64.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;90</td>
                        <td align="char" rowspan="1" colspan="1">22.0</td>
                        <td align="char" rowspan="1" colspan="1">22.9</td>
                        <td align="char" rowspan="1" colspan="1">20.1</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">eGFR, mL/min per 1.73 m<sup>2</sup></td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;60</td>
                        <td align="char" rowspan="1" colspan="1">16.6</td>
                        <td align="char" rowspan="1" colspan="1">14.3</td>
                        <td align="char" rowspan="1" colspan="1">21.1</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">60 to 89</td>
                        <td align="char" rowspan="1" colspan="1">26.1</td>
                        <td align="char" rowspan="1" colspan="1">23.7</td>
                        <td align="char" rowspan="1" colspan="1">31.1</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥90</td>
                        <td align="char" rowspan="1" colspan="1">24.8</td>
                        <td align="char" rowspan="1" colspan="1">22.7</td>
                        <td align="char" rowspan="1" colspan="1">29.0</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Unmeasured</td>
                        <td align="char" rowspan="1" colspan="1">32.5</td>
                        <td align="char" rowspan="1" colspan="1">39.4</td>
                        <td align="char" rowspan="1" colspan="1">18.8</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVEF value</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≤0.40</td>
                        <td align="char" rowspan="1" colspan="1">7.0</td>
                        <td align="char" rowspan="1" colspan="1">7.7</td>
                        <td align="char" rowspan="1" colspan="1">5.5</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;0.40</td>
                        <td align="char" rowspan="1" colspan="1">41.6</td>
                        <td align="char" rowspan="1" colspan="1">46.0</td>
                        <td align="char" rowspan="1" colspan="1">32.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Unmeasured</td>
                        <td align="char" rowspan="1" colspan="1">51.4</td>
                        <td align="char" rowspan="1" colspan="1">46.3</td>
                        <td align="char" rowspan="1" colspan="1">61.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Economic‐geographic region</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Eastern</td>
                        <td align="char" rowspan="1" colspan="1">59.2</td>
                        <td align="char" rowspan="1" colspan="1">58.7</td>
                        <td align="char" rowspan="1" colspan="1">60.2</td>
                        <td align="char" rowspan="3" colspan="1">0.10</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Central</td>
                        <td align="char" rowspan="1" colspan="1">21.2</td>
                        <td align="char" rowspan="1" colspan="1">21.2</td>
                        <td align="char" rowspan="1" colspan="1">21.2</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Western</td>
                        <td align="char" rowspan="1" colspan="1">19.6</td>
                        <td align="char" rowspan="1" colspan="1">20.1</td>
                        <td align="char" rowspan="1" colspan="1">18.6</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Rural/urban</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Rural</td>
                        <td align="char" rowspan="1" colspan="1">38.8</td>
                        <td align="char" rowspan="1" colspan="1">38.1</td>
                        <td align="char" rowspan="1" colspan="1">40.2</td>
                        <td align="char" rowspan="2" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Urban</td>
                        <td align="char" rowspan="1" colspan="1">61.2</td>
                        <td align="char" rowspan="1" colspan="1">61.9</td>
                        <td align="char" rowspan="1" colspan="1">59.8</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Hospital characteristics<xref ref-type="table-fn" rid="tf1-1">*</xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Teaching</td>
                        <td align="char" rowspan="1" colspan="1">80.3</td>
                        <td align="char" rowspan="1" colspan="1">82.3</td>
                        <td align="char" rowspan="1" colspan="1">76.3</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PCI‐capable</td>
                        <td align="char" rowspan="1" colspan="1">60.8</td>
                        <td align="char" rowspan="1" colspan="1">63.4</td>
                        <td align="char" rowspan="1" colspan="1">55.5</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Year</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2001</td>
                        <td align="char" rowspan="1" colspan="1">15.1</td>
                        <td align="char" rowspan="1" colspan="1">13.9</td>
                        <td align="char" rowspan="1" colspan="1">17.7</td>
                        <td align="char" rowspan="3" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2006</td>
                        <td align="char" rowspan="1" colspan="1">28.5</td>
                        <td align="char" rowspan="1" colspan="1">29.9</td>
                        <td align="char" rowspan="1" colspan="1">25.9</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2011</td>
                        <td align="char" rowspan="1" colspan="1">56.3</td>
                        <td align="char" rowspan="1" colspan="1">56.3</td>
                        <td align="char" rowspan="1" colspan="1">56.4</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NSTEMI, non‐ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST‐segment elevation myocardial infarction.</p>
                    </fn>
                    <fn id="tf1-1">
                      <label>*</label>
                      <p>The number (N) reflects the number of patients who were admitted to hospitals with this characteristic.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Outcomes</title>
                <p>We defined the use of ACEI/ARB therapy as prescription of either agent at any point during the hospitalization, as obtained by medical record abstraction. We also assessed the specific type of ACEI/ARB used during hospitalization using the medication that was administered first.</p>
              </sec>
              <sec>
                <title>Stratification of Patients According to Estimated Mortality Risk</title>
                <p>We used the 7‐variable risk score derived from the Cooperative Cardiovascular Project (CCP) to stratify Chinese class I patients by estimated in‐hospital mortality risk.<sup><xref rid="b18" ref-type="bibr">18</xref></sup> This risk score incorporates age, cardiac arrest, anterior or lateral location of MI, systolic blood pressure (SBP), white blood cell (WBC) count, serum Cr, and congestive heart failure. We divided eligible patients into quintiles of estimated in‐hospital mortality risk: ≤1.9%, 2.0% to 3.2%, 3.3% to 5.2%, 5.3% to 8.5%, and &gt;8.5%. Because we only collected blood pressure (BP) at admission, we do not know whether the SBP of patients presenting with hypotension improved during hospitalization. Therefore, we performed a sensitivity analysis excluding patients with BP &lt;90 mm Hg at admission.</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Categorical variables were reported as percentages and differences assessed using the chi‐squared test. We used medians and interquartile range (IQR) to describe continuous variables. We used the Cochran‐Armitage test for trend to study trends in ACEI/ARB use. To generate national estimates, we applied weights proportional to the inverse sampling fraction of patients, to account for differences in the sampling fraction for each time period.</p>
                <p>Factors associated with the use of ACEI/ARB therapy were identified through a multilevel logistic regression model using generalized estimating equation, to account for clustering of patients within hospitals. We selected explanatory variables based on clinical judgment and review of the literature, including demographics, clinical factors, region, and year (<xref ref-type="table" rid="tbl01">Table 1</xref>). We transformed continuous variables, such as age and BP, into categorical variables, using a fractional polynomial approach, according to clinically meaningful cut‐off values, and then created dummy variables. All selected variables were included in the multivariable model to identify predictors of not receiving ACEI/ARB therapy, which are reported as odds ratios (ORs) with 95% confidential intervals (CIs).</p>
                <p>All comparisons were 2‐sided, with a <italic>P</italic>&lt;0.05 considered statistically significant. Statistical analysis was performed using SAS (version 9.2; SAS Institute Inc., Cary, NC) and R (version 3.0.2; R Foundation for Statistical Computing, Vienna, Austria) software.</p>
              </sec>
            </sec>
            <sec sec-type="other">
              <title>Results</title>
              <sec>
                <title>Study Sample</title>
                <p>Of the 16 100 patients with AMI, after excluding patients who transferred in (n=607), transferred out (n=297), died (n=500), or were discharged within 24 hours of admission (n=326), and those with contraindications (n=474), we identified 13 896 patients eligible for ACEI/ARB therapy, which constituted the study cohort. Of these, 13 486 met Chinese Class I and 410 met Chinese Class IIa (<xref ref-type="fig" rid="fig01">Figure 1</xref>); by ACC/AHA guidelines, 11 839 met Class I and 2057 met Class IIa.</p>
                <p>Among Chinese Class I patients, the median age was 66 years (IQR, 56 to 74) and 69.9% were male. CVR factors were common (HTN 52.4%, diabetes 20.6%, and current smoking 34.9%). Of the cohort, 88.2% had a STEMI (42.4% of overall cohort had an anterior STEMI) and 34.6% had HF. At admission, 4.1% presented with an SBP &lt;90 mm Hg. Estimated glomerular filtration rate (eGFR) &lt;60 mL/min per 1.73 m<sup>2</sup> was in 16.6%. LVEF was measured only in half of the study cohort (48.6%), and among those, 14.4% had an LVEF ≤0.40 (<xref ref-type="table" rid="tbl01">Table 1</xref>).</p>
              </sec>
              <sec>
                <title>Use of ACEI/ARB Therapy</title>
                <p>The weighted proportion of ACEI/ARB therapy (95% CI) in Chinese Class I was 62.0% (59.9 to 64.1) in 2001, which increased to 71.4% (70.0 to 72.8) in 2006, but subsequently decreased to 67.6% (65.5 to 68.6) in 2011 (<italic>P</italic>=0.01 for trend). In Chinese Class IIa, the weighted proportion of ACEI/ARB changed little over time (38.6% [32.0 to 45.3] in 2001, 38.9% [33.3 to 44.4] in 2006 and 47.9% [44.9 to 50.9] in 2011, respectively; <italic>P</italic>=0.1 for trend). The weighted rate of ACEI/ARB therapy in ACC/AHA Class I was 66.0% (64.8 to 67.1) in 2001, 73.8% (73.0 to 74.5) in 2006, and 70.4% (69.8 to 70.9) in 2011 (<italic>P</italic>=0.1 for trend), whereas in ACC/AHA Class IIa, it was 40.0% (37.4 to 42.5) in 2001, 50.4% (48.2 to 52.5) in 2006, and 45.8% (44.3 to 47.2) in 2011 (<italic>P</italic>=0.2 for trend; <xref ref-type="fig" rid="fig02">Figure 2</xref>). Baseline characteristics and use of ACEI/ARB therapy in patients with length of stay less than 24 hours are shown in Tables <xref ref-type="table" rid="tbl02">2</xref> and <xref ref-type="table" rid="tbl03">3</xref> respectively. After excluding patients with Cr ≥1.5 mg/dL during hospitalization, the weighted proportions of ACEI/ARB therapy in both Chinese Class I and IIa categories were similar to the primary cohort (<xref ref-type="table" rid="tbl04">Table 4</xref>).</p>
                <table-wrap id="tbl02" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Baseline Demographic and Clinical Characteristics Between Chinese Class I Patients and Patients With Length of Stay Less Than 24 Hours</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Characteristics</th>
                        <th align="center" rowspan="1" colspan="1">Chinese Class I Patients (%) (N=13 486)</th>
                        <th align="center" rowspan="1" colspan="1">Patients With Length of Stay &lt;24 Hours (%) (N=1123)</th>
                        <th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Demographics</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;55</td>
                        <td align="char" rowspan="1" colspan="1">22.2</td>
                        <td align="char" rowspan="1" colspan="1">16.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">55 to 64</td>
                        <td align="char" rowspan="1" colspan="1">23.7</td>
                        <td align="char" rowspan="1" colspan="1">19.2</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">65 to 74</td>
                        <td align="char" rowspan="1" colspan="1">30.1</td>
                        <td align="char" rowspan="1" colspan="1">31.2</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥75</td>
                        <td align="char" rowspan="1" colspan="1">24.0</td>
                        <td align="char" rowspan="1" colspan="1">32.9</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gender</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Male</td>
                        <td align="char" rowspan="1" colspan="1">69.9</td>
                        <td align="char" rowspan="1" colspan="1">60.6</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female</td>
                        <td align="char" rowspan="1" colspan="1">30.1</td>
                        <td align="char" rowspan="1" colspan="1">39.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Cardiovascular risk factors</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="char" rowspan="1" colspan="1">52.4</td>
                        <td align="char" rowspan="1" colspan="1">40.7</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes</td>
                        <td align="char" rowspan="1" colspan="1">20.6</td>
                        <td align="char" rowspan="1" colspan="1">17.7</td>
                        <td align="char" rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Current smoker</td>
                        <td align="char" rowspan="1" colspan="1">34.9</td>
                        <td align="char" rowspan="1" colspan="1">13.2</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Medical history</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="char" rowspan="1" colspan="1">11.5</td>
                        <td align="char" rowspan="1" colspan="1">11.4</td>
                        <td align="char" rowspan="1" colspan="1">0.92</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Chronic renal insufficiency</td>
                        <td align="char" rowspan="1" colspan="1">1.9</td>
                        <td align="char" rowspan="1" colspan="1">2.7</td>
                        <td align="char" rowspan="1" colspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Coronary heart disease</td>
                        <td align="char" rowspan="1" colspan="1">22.6</td>
                        <td align="char" rowspan="1" colspan="1">19.2</td>
                        <td align="char" rowspan="1" colspan="1">0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="char" rowspan="1" colspan="1">10.8</td>
                        <td align="char" rowspan="1" colspan="1">8.3</td>
                        <td align="char" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Clinical characteristics during hospitalization</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">AMI type</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anterior STEMI</td>
                        <td align="char" rowspan="1" colspan="1">42.4</td>
                        <td align="char" rowspan="1" colspan="1">47.8</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non‐anterior STEMI</td>
                        <td align="char" rowspan="1" colspan="1">45.8</td>
                        <td align="char" rowspan="1" colspan="1">40.5</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NSTEMI</td>
                        <td align="char" rowspan="1" colspan="1">11.8</td>
                        <td align="char" rowspan="1" colspan="1">11.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cardiac arrest</td>
                        <td align="char" rowspan="1" colspan="1">2.8</td>
                        <td align="char" rowspan="1" colspan="1">18.9</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cardiogenic shock</td>
                        <td align="char" rowspan="1" colspan="1">6.2</td>
                        <td align="char" rowspan="1" colspan="1">35.4</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart failure</td>
                        <td align="char" rowspan="1" colspan="1">34.6</td>
                        <td align="char" rowspan="1" colspan="1">37.4</td>
                        <td align="char" rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Atrial fibrillation</td>
                        <td align="char" rowspan="1" colspan="1">9.4</td>
                        <td align="char" rowspan="1" colspan="1">9.7</td>
                        <td align="char" rowspan="1" colspan="1">0.77</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP, mm Hg</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;90</td>
                        <td align="char" rowspan="1" colspan="1">4.1</td>
                        <td align="char" rowspan="1" colspan="1">24.6</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">90 to 139</td>
                        <td align="char" rowspan="1" colspan="1">58.5</td>
                        <td align="char" rowspan="1" colspan="1">52.2</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥140</td>
                        <td align="char" rowspan="1" colspan="1">37.4</td>
                        <td align="char" rowspan="1" colspan="1">23.2</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart rate, beats/min</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;60</td>
                        <td align="char" rowspan="1" colspan="1">12.3</td>
                        <td align="char" rowspan="1" colspan="1">17.7</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">60 to 90</td>
                        <td align="char" rowspan="1" colspan="1">65.8</td>
                        <td align="char" rowspan="1" colspan="1">47.8</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;90</td>
                        <td align="char" rowspan="1" colspan="1">22.0</td>
                        <td align="char" rowspan="1" colspan="1">34.5</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">eGFR, mL/min per 1.73 m<sup>2</sup></td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&lt;60</td>
                        <td align="char" rowspan="1" colspan="1">16.6</td>
                        <td align="char" rowspan="1" colspan="1">28.6</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">60 to 89</td>
                        <td align="char" rowspan="1" colspan="1">26.1</td>
                        <td align="char" rowspan="1" colspan="1">18.4</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥90</td>
                        <td align="char" rowspan="1" colspan="1">24.8</td>
                        <td align="char" rowspan="1" colspan="1">11.1</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Unmeasured</td>
                        <td align="char" rowspan="1" colspan="1">32.5</td>
                        <td align="char" rowspan="1" colspan="1">41.9</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVEF value</td>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1"/>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≤0.40</td>
                        <td align="char" rowspan="1" colspan="1">7.0</td>
                        <td align="char" rowspan="1" colspan="1">1.5</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;0.40</td>
                        <td align="char" rowspan="1" colspan="1">41.6</td>
                        <td align="char" rowspan="1" colspan="1">2.5</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Unmeasured</td>
                        <td align="char" rowspan="1" colspan="1">51.4</td>
                        <td align="char" rowspan="1" colspan="1">96.0</td>
                        <td align="char" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Economic‐geographic region</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Eastern</td>
                        <td align="char" rowspan="1" colspan="1">59.2</td>
                        <td align="char" rowspan="1" colspan="1">55.8</td>
                        <td align="char" rowspan="3" colspan="1">0.03</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Central</td>
                        <td align="char" rowspan="1" colspan="1">21.2</td>
                        <td align="char" rowspan="1" colspan="1">24.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Western</td>
                        <td align="char" rowspan="1" colspan="1">19.6</td>
                        <td align="char" rowspan="1" colspan="1">19.9</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Rural/urban</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Rural</td>
                        <td align="char" rowspan="1" colspan="1">38.8</td>
                        <td align="char" rowspan="1" colspan="1">53.8</td>
                        <td align="char" rowspan="2" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Urban</td>
                        <td align="char" rowspan="1" colspan="1">61.2</td>
                        <td align="char" rowspan="1" colspan="1">46.2</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Hospital characteristics<xref ref-type="table-fn" rid="tf2-1">*</xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Teaching</td>
                        <td align="char" rowspan="1" colspan="1">80.3</td>
                        <td align="char" rowspan="1" colspan="1">72.6</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PCI‐capable</td>
                        <td align="char" rowspan="1" colspan="1">60.8</td>
                        <td align="char" rowspan="1" colspan="1">48.1</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Year</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2001</td>
                        <td align="char" rowspan="1" colspan="1">15.1</td>
                        <td align="char" rowspan="1" colspan="1">9.0</td>
                        <td align="char" rowspan="3" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2006</td>
                        <td align="char" rowspan="1" colspan="1">28.5</td>
                        <td align="char" rowspan="1" colspan="1">27.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2011</td>
                        <td align="char" rowspan="1" colspan="1">56.3</td>
                        <td align="char" rowspan="1" colspan="1">64.0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>AMI indicates acute myocardial infarction; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NSTEMI, non‐ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST‐segment elevation myocardial infarction.</p>
                    </fn>
                    <fn id="tf2-1">
                      <label>*</label>
                      <p>The number (N) reflects the number of patients who were admitted to hospitals with this characteristic.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="tbl03" position="float">
                  <label>Table 3.</label>
                  <caption>
                    <p>The Proportion of Patients With Length of Stay Less Than 24 Hours Receiving ACEI/ARB Therapy</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Patients</th>
                        <th align="left" rowspan="1" colspan="1">Died (N=500)</th>
                        <th align="left" rowspan="1" colspan="1">Transferred Out (N=297)</th>
                        <th align="left" rowspan="1" colspan="1">Discharged (N=326)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ACEI/ARB</td>
                        <td align="left" rowspan="1" colspan="1">20.8%</td>
                        <td align="left" rowspan="1" colspan="1">32.0%</td>
                        <td align="left" rowspan="1" colspan="1">27.6%</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="tbl04" position="float">
                  <label>Table 4.</label>
                  <caption>
                    <p>The Weighted Proportion of ACEI/ARB Therapy in Patients With Creatinine &lt;1.5 and ≤3.0 mg/dL by Year by Chinese Class I and Class IIa</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="2" colspan="1">Cr Value</th>
                        <th align="left" rowspan="2" colspan="1">Patients</th>
                        <th align="left" colspan="3" rowspan="1">Received ACEI/ARB, % (95% CI)</th>
                        <th align="center" rowspan="2" colspan="1"><italic>P</italic> for Trend</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">2001</th>
                        <th align="left" rowspan="1" colspan="1">2006</th>
                        <th align="center" rowspan="1" colspan="1">2011</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Cr&lt;1.5</td>
                        <td align="left" rowspan="1" colspan="1">Chinese Class I</td>
                        <td align="left" rowspan="1" colspan="1">62.4 (60.2 to 64.6)</td>
                        <td align="left" rowspan="1" colspan="1">72.5 (71.0 to 74.0)</td>
                        <td align="left" rowspan="1" colspan="1">68.5 (67.4 to 69.6)</td>
                        <td align="char" rowspan="1" colspan="1">&lt;0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Chinese Class IIa</td>
                        <td align="left" rowspan="1" colspan="1">36.5 (23.0 to 50.0)</td>
                        <td align="left" rowspan="1" colspan="1">37.4 (26.2 to 48.6)</td>
                        <td align="left" rowspan="1" colspan="1">48.1 (42.1 to 54.1)</td>
                        <td align="char" rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Cr≤3.0</td>
                        <td align="left" rowspan="1" colspan="1">Chinese Class I</td>
                        <td align="left" rowspan="1" colspan="1">62.0 (59.9 to 64.1)</td>
                        <td align="left" rowspan="1" colspan="1">71.4 (70.0 to 72.8)</td>
                        <td align="left" rowspan="1" colspan="1">67.6 (65.5 to 68.6)</td>
                        <td align="char" rowspan="1" colspan="1">0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Chinese Class IIa</td>
                        <td align="left" rowspan="1" colspan="1">38.6 (32.0 to 45.3)</td>
                        <td align="left" rowspan="1" colspan="1">38.9 (33.3 to 44.4)</td>
                        <td align="left" rowspan="1" colspan="1">47.9 (44.9 to 50.9)</td>
                        <td align="char" rowspan="1" colspan="1">0.1</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Cr, creatinine.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="fig02" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Temporal trends in ACEI/ARB therapy by Chinese Class I and IIa, and ACC/AHA Class I and IIa. ACC/AHA indicates American College of Cardiology/American Heart Association; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g2"/>
                </fig>
                <p>ACEIs were more frequently used than ARBs among Chinese Class I patients across all time periods (58.9% vs. 1.7% in 2001; 65.7% vs. 3.4% in 2006; and 55.7% vs. 10.5% in 2011). The rate of dual therapy with both ACEI and ARB was low (0.6% in 2001, 0.7% in 2006, and 0.5% in 2011, respectively; <xref ref-type="fig" rid="fig03">Figure 3</xref>).</p>
                <fig id="fig03" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Use of ACEI, ARB, and both ACEI/ARB among Chinese Class I patients by year. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g3"/>
                </fig>
                <p>Over the study period, there were significant changes in the specific agents that were used among eligible patients (13 896). Among ACEIs, captopril was the dominant agent used in 2001 (68.8%). This proportion decreased to 23.6% in 2011, with an increase in use of enalapril (27.1% in 2011), benazepril (22.6%), perindopril (14.1%), and fosinopril (8.4%). Among ARBs, valsartan was the dominant agent in 2001 (67.7%), declining to 28.2% in 2011, with an increase in use of irbesartan (25.1% in 2011) and telmisartan (13.8%; <xref ref-type="fig" rid="fig04">Figure 4</xref>A and <xref ref-type="fig" rid="fig04">4</xref>B).</p>
                <fig id="fig04" position="float">
                  <label>Figure 4.</label>
                  <caption>
                    <p>A, ACEI prescription among eligible patients by year. B, ARB prescription among eligible patients by year. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g4"/>
                </fig>
              </sec>
              <sec>
                <title>Use of ACEI/ARB Across Regions</title>
                <p>Rates of ACEI/ARB therapy in 2011 were similar across all 5 regions in China. In rural regions, ACEI/ARB use increased consistently from 2001 to 2011 (<italic>P</italic> for trend=0.006 for Eastern‐rural and <italic>P</italic> for trend=0.01 and 0.009 for Central and Western‐rural, respectively), whereas in urban regions, there was an increase from 2001 to 2006, but a subsequent decrease in 2011 (<italic>P</italic> for trend=0.32 for Eastern‐urban and <italic>P</italic> for trend=0.04 for Central and Western‐urban; <xref ref-type="fig" rid="fig05">Figure 5</xref>).</p>
                <fig id="fig05" position="float">
                  <label>Figure 5.</label>
                  <caption>
                    <p>Regional trends in ACEI/ARB use among Chinese Class I patients by year. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; C/WU, central/western‐urban; CR, central‐rural; ER, eastern‐rural; EU, eastern‐urban; WR, western‐rural.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g5"/>
                </fig>
              </sec>
              <sec>
                <title>Factors Associated With Use of ACEI/ARB</title>
                <p>Patient and hospital characteristics stratified by receipt of ACEI/ARB are shown in <xref ref-type="table" rid="tbl01">Table 1</xref>.</p>
                <p>Significant correlates of ACEI/ARB therapy in multivariable analysis are shown in <xref ref-type="fig" rid="fig06">Figure 6</xref>. Women were less likely to receive ACEI/ARB therapy than men (OR, 0.83; 95% CI, 0.74 to 0.92). Patients with history of stroke (OR, 0.87; 95% CI, 0.76 to 0.99) and chronic renal insufficiency (CRI; OR, 0.72; 95% CI, 0.53 to 0.98) were also less likely to be treated with ACEI/ARB therapy. Patients with nonanterior STEMI and NSTEMI, compared with anterior STEMI, were less likely to receive this therapy (OR, 0.71; 95% CI, 0.65 to 0.78 and OR, 0.79; 95% CI 0.67 to 0.92, respectively). Patients with SBP &lt;90 mm Hg at presentation (OR, 0.55; 95% CI, 0.42 to 0.71, compared to 90 to 139 mm Hg) and those with eGFR &lt;60 mL/min per 1.73 m<sup>2</sup> (OR, 0.79; 95% CI, 0.66 to 0.96, compared with GFR ≥90 mL/min per 1.73 m<sup>2</sup>) were less likely to receive ACEI/ARB. Among patients who had LV function assessed, those with an LVEF ≤0.40 were no more likely to receive ACEI/ARB therapy (OR, 0.93; 95% CI, 0.75 to 1.14), compared with LVEF &gt;0.40. Patients without a measurement of LVEF were less likely to receive therapy, whereas those with unmeasured eGFR were more likely to be treated. The interaction between study year and unmeasured LVEF or eGFR implied that the likelihood of using ACEI/ARB in patients with unmeasured LVEF or eGFR has relatively increased during the past decade (<italic>P</italic> for year×LVEF interaction=0.005; <italic>P</italic> for year×eGFR interaction&lt;0.001). Patients in nonteaching hospitals were less likely to be treated (OR, 0.72; 95% CI, 0.53 to 0.97, compared with teaching hospital).</p>
                <fig id="fig06" position="float">
                  <label>Figure 6.</label>
                  <caption>
                    <p>Factors associated with ACEI/ARB use among Chinese Class I patients in multivariable analysis. Variables associated with ACEI/ARB use are shown along the vertical axis. The strength of effect is shown along the horizontal axis with the vertical line demarcating an odds ratio (OR) of 1 (ie, no association); estimates to the right (ie, &gt;1) are associated with a greater likelihood of ACEI/ARB use, whereas those to the left (ie, &lt;1) indicate a reduced likelihood of ACEI/ARB use. Each dot represents the point estimate of the effect of that variable in the model, whereas the line shows the 95% confidence interval (CI). C‐statistic=0.75. ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NSTEMI, non‐ST‐segment elevation myocardial infarction; SBP, systolic blood pressure; STEMI, ST‐segment elevation myocardial infarction.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g6"/>
                </fig>
              </sec>
              <sec>
                <title>Use of ACEI/ARB Stratified by Estimated Risk of In‐Hospital Mortality</title>
                <p>After excluding patients without measured WBC count or serum Cr, we identified 10 745 patients for the risk model. Among patients stratified by estimated mortality risk, a change in the risk‐treatment pattern was observed over time (<xref ref-type="fig" rid="fig07">Figure 7</xref>A). In 2001, rates of ACE/ARB increased with increasing levels of estimated patient risk (from 62.0% in the lowest‐risk quintile to 72.0% in the highest‐risk quintile; <italic>P</italic> for trend across risk quintiles=0.006). By 2011, however, a risk‐treatment paradox had emerged, with lower rates of ACEI/ARB therapy in higher‐risk groups (from 70.7% in the lowest‐risk quintile to 63.5% in the highest‐risk quintile; <italic>P</italic> for trend across risk quintiles &lt;0.001). The interaction between mortality risk and year reflects that this temporal change in treatment pattern was statistically significant (<italic>P</italic> for interaction &lt;0.001). After excluding patients with BP &lt;90 mm Hg, the results were similar (<xref ref-type="fig" rid="fig07">Figure 7</xref>B).</p>
                <fig id="fig07" position="float">
                  <label>Figure 7.</label>
                  <caption>
                    <p>A, ACEI/ARB use among Chinese Class I patients by year stratified by estimated in‐hospital mortality risk. <italic>P</italic> for trend. <italic>P</italic> for year×mortality risk interaction &lt;0.001. C‐statistic=0.77. B, ACEI/ARB use among Chinese Class I patients after excluding BP &lt;90 mm Hg by year stratified by estimated in‐hospital mortality risk. <italic>P</italic> for trend. <italic>P</italic> for year×mortality risk interaction &lt;0.001. C‐statistic=0.76. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure.</p>
                  </caption>
                  <graphic xlink:href="jah3-4-e001343-g7"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="other">
              <title>Discussion</title>
              <p>In this nationally representative study of patients hospitalized with AMI in China, including both STEMI and NSTEMI, only two thirds of patients with a Class I indication received ACEI/ARB therapy in 2011. Use increased from 2001 to 2006, but subsequently declined in 2011. Use was similarly low across regions, although rural regions continued to improve their use over time. In strata of estimated mortality risk, different patterns of treatment were observed over time. Rates of therapy increased with increasing risk in 2001. However, by 2011, patients with the highest estimated risk of mortality were the least likely to be treated.</p>
              <p>The rate of ACEI/ARB therapy for AMI in patients with Class I indications in China was lower than previous studies in China and that reported in the United States. The Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study between 2004 and 2005 showed higher use of ACEI/ARB therapy (ACEI, 76%; ARB, 6.8% to 10.8%) during hospitalization among all patients with acute coronary syndrome (ACS).<sup><xref rid="b19" ref-type="bibr">19</xref></sup> Also, in the Bridging the Gap on Coronary Heart Disease Secondary Prevention in China (BRIG) study in 2006, the proportion of patients with ST elevation ACS receiving ACEI/ARB during hospitalization was approximately 75%.<sup><xref rid="b20" ref-type="bibr">20</xref></sup> However, both these studies included patients only from selected hospitals. In contrast, our cohort is a nationally representative sample derived through random sampling and thus provides a robust assessment of practice patterns for AMI in China. The rate of ACEI/ARB therapy in 2011 in our study is comparable to the rate in the United States in 2003 (68%).<sup><xref rid="b21" ref-type="bibr">21</xref></sup> By 2009, driven largely by national quality improvement efforts, the proportion of patients receiving ACEI/ARB therapy at discharge had increased to the 77% to 85% range.<sup><xref rid="b22" ref-type="bibr">22</xref></sup> These improvements in the United States suggests that similar initiatives in China may bolster ACEI/ARB utilization.<sup><xref rid="b22" ref-type="bibr">22</xref>–<xref rid="b23" ref-type="bibr">23</xref></sup></p>
              <p>Our findings show that ACEI/ARB therapy remains widely underprescribed in China, and rates of use have improved little over time. Initiation of ACEI therapy early after AMI is beneficial and saves ≈5 lives for every 1000 patients treated in the first month.<sup><xref rid="b4" ref-type="bibr">4</xref></sup> Both Chinese and U.S. guidelines during our study period have consistently endorsed the use of ACEI/ARB therapy early after AMI.<sup><xref rid="b5" ref-type="bibr">5</xref>–<xref rid="b11" ref-type="bibr">11</xref></sup> In China, ACEIs are both widely available and relatively inexpensive (≈$1 for a 30‐day supply).<sup><xref rid="b12" ref-type="bibr">12</xref></sup> Moreover, since 2006, with health care reform in China, medical insurance coverage has rapidly increased and, by 2010, 90% of the entire population had some form of health insurance.<sup><xref rid="b24" ref-type="bibr">24</xref>–<xref rid="b25" ref-type="bibr">25</xref></sup> Nevertheless, we found that one third of patients did not receive either ACEI or ARB therapy.</p>
              <p>Without significant financial constraints to ACEI/ARB use, the reasons for the widespread underuse are unclear, and additional research is needed to illuminate underlying barriers. Potential explanations include difficulties in selecting appropriate patients for ACEI/ARB, concern among providers for side effects, or a lack of practitioner knowledge.<sup><xref rid="b26" ref-type="bibr">26</xref></sup> Quality improvement efforts need to consider these and other potential causes, in order to stimulate wider use of ACEI/ARB for AMI in China.</p>
              <p>Interestingly, in contrast to the trends in ACEI/ARB utilization described herein, other analyses of the China‐PEACE study revealed marked improvements in the use of aspirin, clopidogrel, and statins.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> The relative uptake of clopidogrel and statins is surprising, especially because these medicines are more expensive than ACEIs.<sup><xref rid="b12" ref-type="bibr">12</xref></sup> One possible explanation is that clinical considerations, such as renal dysfunction, figure more prominently in the decision to use ACEI/ARB therapy, compared to statins and antiplatelet agents. In addition, it should be noted that the evidence for statins and clopidogrel has mainly been generated in the past decade, the same time frame as our study, in contrast to the evidence supporting ACEI use, which is older. The publication of this new evidence supporting statin and antiplatelet therapy may have stimulated their uptake at all 3 time points in the China‐PEACE study.</p>
              <p>An important observation from this study was the emergence of a risk treatment paradox in China over the last decade—where high‐risk patients with AMI who stand to benefit the most from treatment were the least likely to receive ACEI/ARB therapy. This pattern of care has been observed in other areas of CVD management in Canada and the United States, including both invasive<sup><xref rid="b27" ref-type="bibr">27</xref></sup> and preventative<sup><xref rid="b28" ref-type="bibr">28</xref>–<xref rid="b29" ref-type="bibr">29</xref></sup> interventions. A recent study using the Get With The Guidelines registry suggested that hospitals participating in quality improvement programs showed improvements in risk treatment paradox over time.<sup><xref rid="b30" ref-type="bibr">30</xref></sup> This highlights the need for similar concerted quality improvement efforts in China to reverse this trend and ensure the delivery of evidence‐based therapies to those who will benefit most.</p>
              <p>Certain factors should be considered in the interpretation of the results of this study. First, our analysis used information based on medical record abstraction, which is dependent on the accuracy and completeness of physician documentation. However, a standardized central abstraction ensured an overall variable agreement of &gt;98%. Second, in the same context, contraindications or intolerance to ACEI/ARB therapy may have been present, but not documented, which would have resulted in an overestimate of the ideal population for ACEI/ARB and a corresponding underestimate of the rate of ACEI/ARB use in ideal patients. Third, we only collected BP measurements at admission, which could have changed over the course of the hospitalization, which could influence the decision to prescribe ACEI/ARB. However, collectively, the reasons for possible underestimation of ACEI/ARB rates are insufficient to explain why nearly 3 in 10 patients did not receive this therapy. In applying stringent criteria for exclusion, we intended to isolate a study sample that most certainly would have benefited from treatment; however, we still found significant underutilization.</p>
            </sec>
            <sec sec-type="other">
              <title>Conclusion</title>
              <p>In this nationally representative study of patients hospitalized with AMI in China, we found underutilization of ACEI/ARB therapy, which extends across regions, and rates of use have not improved appreciably over the past decade. Moreover, with time, a risk treatment paradox has emerged, wherein there is considerable underuse of ACEI/ARB among subgroups at the highest risk for mortality. These findings identify important opportunities for improvement as the Chinese health‐care system reengineers itself to deliver high‐quality care to the rising number of people with AMI. These data can serve as a baseline against which future improvements can be measured.</p>
            </sec>
            <sec>
              <title>Acknowledgments</title>
              <p>The authors appreciate the multiple contributions made by study teams at the China Oxford Center for International Health Research and the Yale‐New Haven Hospital Center for Outcomes Research and Evaluation in the realms of study design and operations, particularly the data collection by Yi Pi, Wuhanbilige Hundei, Haibo Zhang, Lihua Zhang, Xue Du, Wenchi Guan, Xin Zheng, and Yuanlin Guo. The authors appreciate the advice of analysis by Yongfei Wang, Zhenqiu Lin, Xiao Xu, Haiqun Lin, and Shuxia Li. The authors appreciate the editing by Sisi Wang, Sudhakar V. Nuti, and Nicholas Downing. The authors are grateful for the funding support provided by the Chinese government.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data">
                <caption>
                  <p><bold>Appendix</bold> China PEACE-Retrospective AMI Study Site Investigators by Hospital.</p>
                </caption>
                <media xlink:href="jah3-4-e001343-s1.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <title>Sources of Funding</title>
              <fn fn-type="financial-disclosure">
                <p>This project was partly supported by the Research Special Fund for Public Welfare Industry of Health (201202025) from the National Health and Family Planning Commission of China. Dr Ross is supported by the National Institute on Aging (K08 AG032886) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. Dr Krumholz is supported by grant U01 HL105270‐05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. The sponsors had no role in the design or conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation or approval of the manuscript.</p>
              </fn>
            </fn-group>
            <fn-group>
              <title>Disclosures</title>
              <fn fn-type="financial-disclosure">
                <p>Dr Ross and Dr Krumholz report being the recipient of research grants from Medtronic and Johnson &amp; Johnson, through Yale University, to develop methods of clinical trial data sharing. Dr Krumholz reports that he is the chair of a cardiac scientific advisory board for United Health. Dr Ross reports that he is a member of a scientific advisory board for FAIR Health, Inc. Dr Masoudi receives salary support from the American College of Cardiology for his role as the Senior Medical Officer of the National Cardiovascular Data Registries. The authors declare no other relevant conflicts of interest.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="b1">
                <mixed-citation publication-type="journal"><article-title>GISSI‐3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6‐week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico</article-title>. <source>Lancet</source>. <year>1994</year>;
<volume>343</volume>:<fpage>1115</fpage>-<lpage>1122</lpage>.<pub-id pub-id-type="pmid">7910229</pub-id></mixed-citation>
              </ref>
              <ref id="b2">
                <mixed-citation publication-type="journal"><article-title>ISIS‐4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS‐4 (Fourth International Study of Infarct Survival) Collaborative Group</article-title>. <source>Lancet</source>. <year>1995</year>;
<volume>345</volume>:<fpage>669</fpage>-<lpage>685</lpage>.<pub-id pub-id-type="pmid">7661937</pub-id></mixed-citation>
              </ref>
              <ref id="b3">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Velazquez</surname><given-names>EJ</given-names></name><name><surname>Rouleau</surname><given-names>JL</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Van de Werf</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>H</given-names></name><name><surname>Leimberger</surname><given-names>JD</given-names></name><name><surname>Henis</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Zelenkofske</surname><given-names>S</given-names></name><name><surname>Sellers</surname><given-names>MA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name></person-group><article-title>Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both</article-title>. <source>N Engl J Med</source>. <year>2003</year>;
<volume>349</volume>:<fpage>1893</fpage>-<lpage>1906</lpage>.<pub-id pub-id-type="pmid">14610160</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <mixed-citation publication-type="journal"><collab>ACE Inhibitor Myocardial Infarction Collaborative Group</collab>. 
<article-title>Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group</article-title>. <source>Circulation</source>. <year>1998</year>;
<volume>97</volume>:<fpage>2202</fpage>-<lpage>2212</lpage>.<pub-id pub-id-type="pmid">9631869</pub-id></mixed-citation>
              </ref>
              <ref id="b5">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Braniff</surname><given-names>BA</given-names></name><name><surname>Brooks</surname><given-names>NH</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Hillis</surname><given-names>LD</given-names></name><name><surname>Hiratzka</surname><given-names>LF</given-names></name><name><surname>Rapaport</surname><given-names>E</given-names></name><name><surname>Riegel</surname><given-names>BJ</given-names></name><name><surname>Russell</surname><given-names>RO</given-names></name><name><surname>Smith</surname><given-names>EE</given-names><suffix>Jr</suffix></name><name><surname>Weaver</surname><given-names>WD</given-names></name></person-group><article-title>ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)</article-title>. <source>J Am Coll Cardiol</source>. <year>1996</year>;
<volume>28</volume>:<fpage>1328</fpage>-<lpage>1428</lpage>.<pub-id pub-id-type="pmid">8890834</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Chavey</surname><given-names>WE</given-names></name><name><surname>Fesmire</surname><given-names>FM</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Levin</surname><given-names>TN</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name></person-group><article-title>ACC/AHA 2007 guidelines for the management of patients with unstable angina/non‐ST‐Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non‐ST‐Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;
<volume>50</volume>:<fpage>e1</fpage>-<lpage>e157</lpage>.<pub-id pub-id-type="pmid">17692738</pub-id></mixed-citation>
              </ref>
              <ref id="b7">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Hand</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Halasyamani</surname><given-names>LK</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Lamas</surname><given-names>GA</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Pearle</surname><given-names>DL</given-names></name><name><surname>Sloan</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Anbe</surname><given-names>DT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Buller</surname><given-names>CE</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Tarkington</surname><given-names>LG</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name></person-group><article-title>2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;
<volume>51</volume>:<fpage>210</fpage>-<lpage>247</lpage>.<pub-id pub-id-type="pmid">18191746</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Gara</surname><given-names>PT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Fesmire</surname><given-names>FM</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Linderbaum</surname><given-names>JA</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Ou</surname><given-names>N</given-names></name><name><surname>Radford</surname><given-names>MJ</given-names></name><name><surname>Tamis‐Holland</surname><given-names>JE</given-names></name><name><surname>Tommaso</surname><given-names>CL</given-names></name><name><surname>Tracy</surname><given-names>CM</given-names></name><name><surname>Woo</surname><given-names>YJ</given-names></name><name><surname>Zhao</surname><given-names>DX</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Albert</surname><given-names>NM</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>DeMets</surname><given-names>D</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Kovacs</surname><given-names>RJ</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name></person-group><article-title>2013 ACCF/AHA guideline for the management of ST‐elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2013</year>;
<volume>127</volume>:<fpage>e362</fpage>-<lpage>e425</lpage>.<pub-id pub-id-type="pmid">23247304</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <mixed-citation publication-type="journal"><collab>China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Editorial Board of Chinese Journal of Circulation</collab>. 
<article-title>Guideline for diagnosis and treatment of patients with ST‐elevation myocardial infarction</article-title>. <source>China J Circ</source>. <year>2001</year>;
<volume>16</volume>:<fpage>407</fpage>-<lpage>422</lpage>.</mixed-citation>
              </ref>
              <ref id="b10">
                <mixed-citation publication-type="journal"><collab>China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology</collab>. 
<article-title>Guideline for diagnosis and treatment of patients with unstable angina and non‐ST‐elevation myocardial infarction</article-title>. <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>. <year>2007</year>;
<volume>35</volume>:<fpage>295</fpage>-<lpage>304</lpage>.<pub-id pub-id-type="pmid">17711651</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <mixed-citation publication-type="journal"><collab>China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology</collab>. 
<article-title>Guideline for diagnosis and treatment of patients with ST‐elevation myocardial infarction</article-title>. <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>. <year>2010</year>;
<volume>38</volume>:<fpage>675</fpage>-<lpage>690</lpage>.<pub-id pub-id-type="pmid">21055132</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Moran</surname><given-names>AE</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Coxson</surname><given-names>PG</given-names></name><name><surname>Heidenreich</surname><given-names>PA</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name></person-group><article-title>Cost‐effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in china</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2014</year>;
<volume>7</volume>:<fpage>78</fpage>-<lpage>85</lpage>.<pub-id pub-id-type="pmid">24425706</pub-id></mixed-citation>
              </ref>
              <ref id="b13">
                <element-citation publication-type="other">
                  <article-title>The World Bank. Toward a healthy and harmonious life in China: stemming the rising tide of non‐communicable diseases</article-title>
                  <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.worldbank.org/content/dam/Worldbank/document/NCD_report_en.pdf">http://www.worldbank.org/content/dam/Worldbank/document/NCD_report_en.pdf</ext-link>. Accessed November 27, 2013.</comment>
                </element-citation>
              </ref>
              <ref id="b14">
                <mixed-citation publication-type="other"><collab>National Bureau of Statistics of China</collab>. 
<article-title>China statistical yearbook 2011</article-title><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.stats.gov.cn/tjsj/ndsj/2011/indexch.htm">http://www.stats.gov.cn/tjsj/ndsj/2011/indexch.htm</ext-link>. Accessed November 27, 2013.</comment></mixed-citation>
              </ref>
              <ref id="b15">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharmarajan</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>The China Patient‐Centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective study of acute myocardial infarction: study design</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2013</year>;
<volume>6</volume>:<fpage>732</fpage>-<lpage>740</lpage>.<pub-id pub-id-type="pmid">24221838</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>Rathore</surname><given-names>SS</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Havranek</surname><given-names>EP</given-names></name><name><surname>Curtis</surname><given-names>JP</given-names></name><name><surname>Foody</surname><given-names>JM</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name></person-group><article-title>National patterns of use and effectiveness of angiotensin‐converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction</article-title>. <source>Circulation</source>. <year>2004</year>;
<volume>110</volume>:<fpage>724</fpage>-<lpage>731</lpage>.<pub-id pub-id-type="pmid">15289383</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>ST‐segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE‐Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data</article-title>. <source>Lancet</source>. <year>2014</year>10.1016/S0140‐6736(14)60921‐1</mixed-citation>
              </ref>
              <ref id="b18">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Radford</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Marciniak</surname><given-names>TA</given-names></name></person-group><article-title>Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment</article-title>. <source>Circulation</source>. <year>1999</year>;
<volume>99</volume>:<fpage>2986</fpage>-<lpage>2992</lpage>.<pub-id pub-id-type="pmid">10368115</pub-id></mixed-citation>
              </ref>
              <ref id="b19">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Harris</surname><given-names>P</given-names></name><name><surname>Algert</surname><given-names>C</given-names></name><name><surname>Groenestein</surname><given-names>P</given-names></name><name><surname>Turnbull</surname><given-names>F</given-names></name></person-group><article-title>Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes</article-title>. <source>Heart</source>. <year>2008</year>;
<volume>94</volume>:<fpage>554</fpage>-<lpage>560</lpage>.<pub-id pub-id-type="pmid">17932092</pub-id></mixed-citation>
              </ref>
              <ref id="b20">
                <mixed-citation publication-type="journal"><collab>Bridging the Gap on coronary Heart Disease Secondary Prevention in China</collab>. 
<article-title>Analysis of current treatment practice and outcomes for in‐patients with ST‐segment elevation acute coronary syndrome in 31 provinces of China</article-title>. <source>Beijing Da Xue Xue Bao</source>. <year>2011</year>;
<volume>43</volume>:<fpage>440</fpage>-<lpage>445</lpage>.<pub-id pub-id-type="pmid">21681279</pub-id></mixed-citation>
              </ref>
              <ref id="b21">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doubeni</surname><given-names>C</given-names></name><name><surname>Bigelow</surname><given-names>C</given-names></name><name><surname>Lessard</surname><given-names>D</given-names></name><name><surname>Spencer</surname><given-names>F</given-names></name><name><surname>Yarzebski</surname><given-names>J</given-names></name><name><surname>Gore</surname><given-names>J</given-names></name><name><surname>Gurwitz</surname><given-names>J</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name></person-group><article-title>Trends and outcomes associated with angiotensin‐converting enzyme inhibitors</article-title>. <source>Am J Med</source>. <year>2006</year>;
<volume>119</volume>:<fpage>616.e9</fpage>-<lpage>616.e16</lpage>.<pub-id pub-id-type="pmid">16828635</pub-id></mixed-citation>
              </ref>
              <ref id="b22">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bainey</surname><given-names>KR</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Hernandez</surname><given-names>AF</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Peacock</surname><given-names>WF</given-names></name><name><surname>Laskey</surname><given-names>WK</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Schwamm</surname><given-names>LH</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name></person-group><article-title>Use of renin‐angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines‐Coronary Artery Disease Program</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2014</year>;
<volume>7</volume>:<fpage>227</fpage>-<lpage>235</lpage>.<pub-id pub-id-type="pmid">24569634</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Messenger</surname><given-names>JC</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Klein</surname><given-names>LW</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>McKay</surname><given-names>C</given-names></name><name><surname>Hewitt</surname><given-names>K</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;
<volume>56</volume>:<fpage>254</fpage>-<lpage>263</lpage>.<pub-id pub-id-type="pmid">20633817</pub-id></mixed-citation>
              </ref>
              <ref id="b24">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Launch of the health‐care reform plan in China</article-title>. <source>Lancet</source>. <year>2009</year>;
<volume>373</volume>:<fpage>1322</fpage>-<lpage>1324</lpage>.<pub-id pub-id-type="pmid">19376436</pub-id></mixed-citation>
              </ref>
              <ref id="b25">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name></person-group><article-title>Report from China: health insurance in China–evolution, current status, and challenges</article-title>. <source>Int J Health Serv</source>. <year>2012</year>;
<volume>42</volume>:<fpage>177</fpage>-<lpage>195</lpage>.<pub-id pub-id-type="pmid">22611649</pub-id></mixed-citation>
              </ref>
              <ref id="b26">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Turnbull</surname><given-names>F</given-names></name></person-group><article-title>Evidence‐based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study</article-title>. <source>Am Heart J</source>. <year>2009</year>;
<volume>157</volume>:<fpage>509</fpage>-<lpage>516.e1</lpage>.<pub-id pub-id-type="pmid">19249422</pub-id></mixed-citation>
              </ref>
              <ref id="b27">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>AT</given-names></name><name><surname>Yan</surname><given-names>RT</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Fung</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name><name><surname>Fitchett</surname><given-names>DH</given-names></name><name><surname>Langer</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>SG</given-names></name></person-group><article-title>Management patterns in relation to risk stratification among patients with non‐ST elevation acute coronary syndromes</article-title>. <source>Arch Intern Med</source>. <year>2007</year>;
<volume>167</volume>:<fpage>1009</fpage>-<lpage>1016</lpage>.<pub-id pub-id-type="pmid">17533203</pub-id></mixed-citation>
              </ref>
              <ref id="b28">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PN</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Hernandez</surname><given-names>AF</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name></person-group><article-title>Treatment and risk in heart failure: gaps in evidence or quality?</article-title><source>Circ Cardiovasc Qual Outcomes</source>. <year>2010</year>;
<volume>3</volume>:<fpage>309</fpage>-<lpage>315</lpage>.<pub-id pub-id-type="pmid">20388872</pub-id></mixed-citation>
              </ref>
              <ref id="b29">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>Mamdani</surname><given-names>M</given-names></name><name><surname>Alter</surname><given-names>DA</given-names></name></person-group><article-title>Lipid‐lowering therapy with statins in high‐risk elderly patients: the treatment‐risk paradox</article-title>. <source>JAMA</source>. <year>2004</year>;
<volume>291</volume>:<fpage>1864</fpage>-<lpage>1870</lpage>.<pub-id pub-id-type="pmid">15100205</pub-id></mixed-citation>
              </ref>
              <ref id="b30">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motivala</surname><given-names>AA</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Srinivas</surname><given-names>VS</given-names></name><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Hernandez</surname><given-names>AF</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name></person-group><article-title>Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?</article-title><source>J Am Coll Cardiol</source>. <year>2011</year>;
<volume>58</volume>:<fpage>1760</fpage>-<lpage>1765</lpage>.<pub-id pub-id-type="pmid">21996387</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
